Heron says CMS granted pass-through payment status for Aponvie

Heron Therapeutics earlier announced that CMS has approved transitional pass-through status for Aponvie injectable emulsion, which will be established for three years beginning April 1 under C-code C9145. Aponvie was approved by the U.S. Food and Drug Administration for intravenous use in adults for the prevention of postoperative nausea and vomiting, or PONV, and became commercially available on March 6, the company noted. "The granting of pass-through status for Aponvie further facilitates patient access and streamlines billing and reimbursement for all HOPD and ASC settings, which is important with over 70% of the surgery opportunity being conducted in these outpatient settings of care. Receiving pass-through only days after the U.S. launch is encouraging and will provide patients undergoing surgery that are at risk for developing PONV an easy to use, convenient, and highly effective treatment option," said Barry Quart, Pharm.D., Chairman and CEO of Heron.